

Neurology Medical Group of Diablo Valley
400 Taylor Blvd. Ste 301
Pleasant Hill, CA 94523
Phone: 925-602-7060
Fax: 925-602-7070

Raymond Martin Stephens , MD

Certifications

American Board of Psychiatry and Neurology- Vascular Neurology	2008
American Board of Electrodiagnostic Medicine - EMG & Neuromuscular Disease	1986
American Board of Psychiatry and Neurology - Neurology	1984
American Board of Qualifications in Electroencephalography - EEG	1982

Licensure

Primary MD - G40939, California

Academic Degrees

MD - University of California San Diego, San Diego, CA	1978
AB - Physiology, University of California Berkeley, Berkeley, CA	1974
Physics Courses - University of Santa Clara, Santa Clara, CA	1972

Residencies and Internships

Chief Resident - Neurology, University of California San Diego, San Diego, CA	1981 - 1982
Resident - Neurology, University of California San Diego, San Diego, CA	1979 - 1982
Internship - Internal Medicine, University of Michigan, Ann Arbor, MI	1978 - 1979

Professional Societies

American Heart Association/American Stroke Association
National Stroke Association
Bay Area Stroke Society
American Association of Neuromuscular and Electrodiagnostic Medicine
American Academy of Neurology
California Medical Association

Experience

Private Practice of Neurology - Neurology Medical Group of Diablo Valley, Walnut Creek, CA	1982 - present
--	----------------

Appointments

Director Stroke Program Primary Stroke Center John Muir Health System	2004 - present
---	----------------

Assistant Clinical Professor of Neurology, University of California Davis, Davis, CA	1982 - 1985
Assistant Clinical Professor - Neurology (Pediatric Neurology), University of California San Francisco, San Francisco, CA	1982 - 1984

Awards

Physician Excellence Award John Muir Concord Campus	Oct 2009
Heart of Gold Award Receptient American Heart Association	May 2009
Bay Area Consumer's Checkbook- Listed in Best Bay Area Medical Specialists San Francisco Magazine-	Winter 1999
Listed in 500 Best MD's in Bay Area	January, 2001
Student Teaching Award in Neurology	1982
Highest Honors - University of California Berkeley, Berkeley, CA	1974
Outstanding Student Award, Physiology - University of California Berkeley, Berkeley, CA	1974
Phi Beta Kappa - University of California Berkeley, Berkeley, CA	1974

Current Hospital Affiliations

John Muir Medical Center - Walnut Creek, CA Campus	(JCAHO certified primary stroke center)
John Muir Medical Center - Concord, CA Campus	(JCAHO certified primary stroke center)

Research Activities

PRINCIPAL INVESTIGATOR

A phase IIB Study to evaluate the Safety and Efficacy of Infrared Laser Transcranial Stimulation in Acute Stroke: NEST II	2007 - 2008
A phase II Multicenter Two-Part Study to evaluate the Safety and Efficacy of V10153 In Acute Ischemic Stroke	2006 – 2007
A phase III Randomized Multicenter Clinical Trial of High-dose Human Albumin Therapy for Neuroprotection in Acute Ischemic Stroke	2006 – present
A double-blind, active and placebo-controlled study of Aggrenox® vs. Clopidogrel + aspirin, with and without Micardis® (PRoFESS)	2003 – 2008
A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess The Efficacy and Safety of Intravenous NXY-059 In Acute Ischemic Stroke (SAINT II)	2003 – 2006
A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess The Safety of Intravenous NXY-059 In Acute Cerebral Hemorrhage (CHANT)	2003 – 2005
A Prospective, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the Starflex Septal Closure System vs. Best Medical Therapy in Patients with a Stroke	2003 - present

and/or TIA due to Presumed Paradoxical Embolism through a Patent Foramen Ovale

A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled, Fixed Dose Response Study Comparing the Efficacy and Safety of Sumanitrolol versus Placebo in Patients with Early Parkinson's Disease	2003 - 2005
A Multicenter, Prospective and Retrospective, Long-Term Observational Study of AVONEX® and Rebif® to Determine the Efficacy, Tolerability, and Safety in Subjects with Relapsing Multiple Sclerosis (MS) (PROOF)	2003 – 2004
Phase I, A Single Rising Dose Study of FK506 Lipid Complex (LCG) in Patients With Recent Ischemic Stroke	2002 – 2003
A Multi-Center, open-label, randomized, 4-way crossover trial of the safety and Efficacy of Tizanidine Hydrochloride Capsules versus Zanaflex® (Tizanidine Hydrochloride) Tablets taken under fed and fasted conditions in patients with Moderate to severe Spasticity	2002
A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of Sumanitrolol versus Placebo or Ropinirole in Patients with Early Parkinson's Disease	2002 – 2003
Open-Label, Long-Term, Flexible Dose Study of Safety, Tolerability and Therapeutic Response in Patients with Parkinson's Disease: PNU-95666E	2002 – 2004
Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attack or Ischemic Stroke: A Randomized, Double-Blind Study, With 18 Months Follow-up. (MATCH)	2001 – 2004
A Randomized, Placebo-Controlled, Three Treatment Arm Study to Determine the Safety and Efficacy of Argatroban Injection in Patients with Acute Ischemic Stroke	2001 – 2002
12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Preliminary Study to Determine the Efficacy and Safety of Donepezil Hydrochloride (E2020) in Patients With Persistent Mild to Moderate Memory Impairments Resulting From a Single Closed Head Injury	2001 – 2002
Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Effects of YM872 on Lesion Volume as Measured by Diffusion, Perfusion and FLAIR Magnetic Resonance Imaging in Patients with Acute Ischemic Stroke (ARTIST MRI)	2001 - 2003
Multicenter, Stratified, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Neurologic Function and Disability in Patients with Acute Ischemic Stroke Given Tissue Plasminogen Activator Plus YM872 or Tissue Plasminogen Activator Plus Placebo (ARTIST+)	2001 - 2003
Phase III Multicenter, Double-Blind, Parallel-Group Placebo Controlled Study of the Effect of Riluzole 50 mg BID or 100 mg BID on the Progression of Parkinson's Disease in Patients Treated with L-Dopa or Dopamine Agonist	2001
Acute Ischemic Stroke Protocol 161-106, Phase II	2000
"Blockade of the GP IIB/IIIa Receptor to Avoid Vascular Occlusion (BRAVO), Phase III."	1999 – 2001
A Phase III, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study	1999 – 2000

of Hu23F2G (LeukArrest™) in Patients with Acute Ischemic Stroke.

"A 4-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Three Dose Levels of Compound When Administered Daily for 28 Days by Subcutaneous Injection on Diabetic Painful Neuropathy in Patients with Type 1 or Type 2 Diabetes Mellitus." 1998 – 1999

The Acute Stroke Study in Ischemic Stroke (Class-I): "A Double-Blind, Parallel-Group, Multinational, Multicenter Study of the Efficacy and Safety of IV Compound Compared to Placebo in Patients with Acute Ischemic Stroke." 1997 – 2000

The Acute Stroke Study in Acute Intracerebral Hemorrhage (Class-H): A Double-Blind, Parallel-Group, Multinational, Multicenter Study of Safety of IV Compound Compared to Placebo in Patients with Acute Intracerebral Hemorrhage." 1997 – 1999

The Acute Stroke Study in t-PA Treated Ischemic Stroke (Class-T): "A Double-Blind, Parallel-Group, Multinational, Multicenter Study of the Safety of IV Compound Compared to Placebo in Patients Treated with t-PA (Tissue Plasminogen Activator) for Acute Ischemic Stroke." 1997 – 1999

"Lubeluzole Int-13 Acute Stroke Study." 1997

"t-PA Acute Stroke less than 3 hr Study, Phase IV." 1997

"t-PA 3 to 5 Hour Acute Stroke Study." 1996

"Open Label, Multicenter Trial of the Safety and Efficacy of Compound in the Treatment of Alzheimer's Disease." 1996

"Enlimomab Acute Stroke Study, Phase III." 1995 – 1996

"DHE 454 Migraine Study, Phase III." 1995

"Structural analysis of hair roots for assessment of malnutrition in large populations. Assistant World Health Organization Consultant to Guatemala, with application of above technique. (University of California, Berkeley, with Dr. Robert Bradfield) 1975

"Structural analysis of chloroplast membranes using electron spin resonance technique." 1973 – 1974 (University of California Physiology Degree Thesis with Dr. Lester packer)

SUBINVESTIGATOR

A Randomized, Rater-blinded, Multicenter, Parallel-group Study Comparing the Efficacy and Safety of Betaseron® 250µg Subcutaneously Every Other Day with Avonex® 30µg Intramuscularly Once per Week in Relapsing-remitting Multiple Sclerosis Patients Previously Treated with Avonex® (ABOVE) 2003 – 2005

A Prospective, 26-Week, Open-label, Multi-center Study Evaluating the Efficacy And Safety of Exelon (rivastigmine tartrate) 3 – 12 mg/day in Patients with Mild To Moderate Alzheimer's Disease Who Are Responding Poorly to Aricept® (donepezil) Treatment (EXCEL) 2003 – 2004

Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) 2003 – 2004

E2020-A001-319 A 24-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy, Safety and Tolerability of Donepezil Hydrochloride (E2020) in Patients with Dementia Associated with Cerebrovascular Disease	2003– 2004
Medical Index for Neuromuscular Data (MIND) Registry	2002 – 2005
Randomized, Double-Blind, Parallel Group Study of the Safety and Efficacy of Latranal Compared to Doxepin Cream and Placebo in Patients with Chronic Low Back Pain	2001
Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor H 376/95 Compared with Dose-Adjusted Warfarin (Coumadin©) in the Prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation (SPORTIF V)	2000 – 2003
Phase II, 12 Week, Randomized, Double-Blind, Placebo Controlled, Multicenter Study Evaluating the Safety and Efficacy of Three Fixed Doses of Oral CP-457,920 (30 mg QD, 60 mg BID and 120 mg BID) and Donepezil in Outpatients with Alzheimer’s Disease	2000 – 2002
Lamictal® in Combination with Newer and Older Antiepileptic Drugs and as Monotherapy: A Practical Clinical Assessment of Tolerability and Clinical Effectiveness (The TARGET Study: <u>T</u> rial to <u>A</u> ssess and <u>R</u> efine <u>G</u> lobal <u>E</u> pilepsy <u>T</u> reatment)”	1999 – 2000
“The Safety and Efficacy of MK-0966 in Slowing the Progression of the Symptoms of Alzheimer’s Disease”	1999 – 2000
“A 24-Month, Double-Blind, Randomized, Placebo-Controlled, Fixed-Dose, Parallel-Group, Multicenter Study of Zenerestat in the Treatment of Diabetic Neuropathy”	1999 – 2000
Pregabalin BID, Open-Label, Add-On Trial: "An Open-Label, Multicenter, Follow-On Study to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures."	1998 – 2005
Pregabalin BID Add-On Trial: "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study in Patients with Partial Seizures."	1998 – 1999
"Topamax Monotherapy Comparison Trial to Standard Monotherapy in the Treatment of Newly Diagnosed Epilepsy."	1998 – 2000
An Open-Label Study to Evaluate the Safety and Efficacy of 1.5 mg b.i.d. (3 mg/day) through 6 mg b.i.d.(12 mg/day) of Exelon in Patients with Mild to Severe Probable Alzheimer's Disease in the Community Setting."	1997
"NGF in Diabetic Polyneuropathy, Phase III."	1998
“Design of cryogenic magnetic shield device for lunar magnetic field experiments.” (Ames Research Center: Apollo 12 Lunar Magnetometer Project)	1971